Finerenone shows superior survival and kidney protection over spironolactone in diabetic kidney disease

Researchers from National Taiwan University Hospital and collaborating institutions have demonstrated that finerenone, a new-generation nonsteroidal mineralocorticoid receptor antagonist (MRA), significantly reduces the risk of death and major…

Continue Reading

News Source: medicalxpress.com